SALT LAKE CITY--(BUSINESS WIRE)--Paterna Biosciences, a ground-breaking innovator in biotechnology and reproductive health, is pleased to announce Dr. Kyle Orwig has joined the company as a co-founder.
As Paterna, a biotechnology company addressing male infertility by pioneering in vitro spermatogenesis, continues to push the boundaries of scientific discovery and advance its mission to improve human reproductive health, Orwig's extensive expertise and contributions to in vitro spermatogenesis and male fertility preservation in oncofertility make him an invaluable asset to the company. Paterna’s other co-founders, Jim Hotaling, Brad Cairns and Jingtao Guo, have co-authored articles with Orwig and view his knowledge, team approach and experience as an invaluable addition to Paterna.
Kyle Orwig brings a reputation and track record of more than two decades for driving advancements in our understanding of spermatogenesis, the germ cell lineage, fertility, and infertility. In addition to his co-founder role, Orwig is currently professor of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh. He is the founding director of the UPMC Magee Center for Reproduction and Transplantation and leads the Orwig lab at the Magee-Womens Research Institute and Magee-Womens Hospital of the University of Pittsburgh.
Paterna Biosciences CEO Ed Rowland said, "Paterna Biosciences is thrilled to welcome Kyle Orwig to our team. His wealth of experience and leadership in male reproductive biology aligns perfectly with our commitment to expanding the boundaries of reproductive health research, and creating practical solutions for couples who have challenges in conceiving. We know Kyle's expertise will play a crucial role in advancing our mission to develop safe, effective in vitro spermatogenesis, enhance human reproductive well-being and increase the success rate of healthy IVF births."
Throughout his career, Orwig has demonstrated a passion for translating scientific discoveries into real-world applications. His collaborative approach to research exemplifies Paterna's commitment to foster interdisciplinary partnerships.
"I am honored and excited to join the exceptional team at Paterna Biosciences, many of them longtime colleagues," said Orwig. "I hope to continue its groundbreaking work in spermatogenesis and to further the company's mission to advance reproductive health."
Paterna Biosciences is an innovator in the biotechnology sector in reproductive health. The addition of Orwig to the leadership team further solidifies the company's position as a global leader in the field, poised to make available solutions for reproductive health.
For more information about Paterna Biosciences please visit www.paternabio.com.
About Paterna Biosciences
Paterna Biosciences is a leading biotechnology company dedicated to advancing reproductive health through cutting-edge research and innovative technologies. With a commitment to scientific excellence, Paterna is at the forefront of developing in vitro spermatogenesis for the treatment of male infertility. By “growing sperm in a dish,” Paterna empowers men and couples with infertility, and healthcare professionals in the field of reproductive biology.